Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Behandling av kronisk obstruktiv lungesykdom (KOLS) med lungediffusjonsdysfunksjon av REGEND001

23. september 2026 oppdatert av: Regend Therapeutics

Et multisenter, randomisert, enkeltblindt, placebo-parallellkontrollert forskning av REGEND001 autologt terapiprodukt for behandling av kronisk obstruktiv lungesykdom (KOLS) med lungediffusjonsdysfunksjon

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

58

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • China-Japan Friendship Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina
        • The Southwest Hospital of AMU
    • Guangdong
      • Guangzhou, Guangdong, Kina
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Xiangya Hospital of Central South University
    • Jiangsu
      • Suzhou, Jiangsu, Kina, 215006
        • The First Affiliated Hospital of Soochow University
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • The First Affiliated Hospital of Nanchang University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Shanghai East Hospital
      • Shanghai, Shanghai Municipality, Kina
        • Zhongshan Hospital affiliated to Fudan University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female, aged 40 to 75 at the time of signing informed consent.
  • Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD).
  • The ratio of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)FEV1/FVC is < 70% after inhalation of bronchodilators.
  • The diffusion function of carbon monoxide (DLCO) is ≥ 20% and < 80% of the predicted value at screening.
  • Tolerated to pulmonary function tests.
  • Tolerated to bronchoscopy
  • Voluntary to sign the informed consent, coordinated to finish the trial-related procedures and tests, and capable of recording or stating the change of disease condition in a relatively complete manner.

Exclusion Criteria:

  • Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);

  • Subjects with a positive result for any of the following tests at screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. But except the followings:

    1. Hepatitis B virus carriers (only HBsAg positive without any hepatitis symptom or sign, and all liver function tests present normal results or abnormal markers without clinical significance by the assessment of investigators);
    2. Cured hepatitis C patients (negative in HCV ribonucleic acid (RNA) test);
  • Subject with assessed survival time of < 1 year by investigators at screening;

  • Subject with malignant tumors or a history of malignant tumors at screening;

  • Subject with infections in lung or other sites, requiring intravenous drug treatment within a week prior to screening;

  • Subject with more than 4 moderate-to-severe AECOPD, resulting in hospitalization within a year prior to screening;

  • Subject with one or more pathogenetic or serologic findings of the novel coronavirus infection, or symptoms of suspected infection within 6 weeks prior to screening;

  • Subject with a history of invasive or noninvasive mechanical ventilation within 4 weeks prior to screening;

  • Subject who has taken prednisone tablets orally at a dose of ≥ 20 mg/day (or equivalent amount of other oral corticosteroids) within 4 weeks prior to screening;

  • Subject with major lung diseases other than COPD by assessment of investigators at screening;

  • Subject with severe systemic diseases other than lung within 6 months prior to screening and assessed to be inappropriate to participate in this trial by investigators;

  • Subject with severe anemia or poorly controlled granulocyte deficiency, thrombocytopenia by assessment of investigators;

  • Subject with abnormal coagulation and assessed to be negative for the safety of fiberoptic bronchoscopy operations at screening;

  • Subject requiring long-term anticoagulation therapy of using antiplatelet coagulant therapeutic agents and disable to discontinue their medications 1 week prior to cell collection and cell infusion as assessed by investigators;

  • Subject with a risk of suicide, a history of mental illness or a history of epilepsy at screening;

  • Subject with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening;

  • Subject participated in other clinical trials with interventions within 3 months prior to screening;

  • Investigators, co-investigators, research coordinators, employees of research participants or research centers, or their family members;

  • Any circumstance considered to probably increase the risk of patients or interfere with the clinical trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Placebo

Transplantation of Placebo

Eksperimentell: REGEND001 cell therapy

REGEND001 cell therapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Responsive rate (RR)
Tidsramme: 12 weeks after treatment, 24 weeks after treatment

Ratio of subjects responsive to the treatment. Subject is considered to be responsive to the treatment as (1) the lung diffusing capacity for carbon monoxide (DLCO) improvement meets MCID (minimal clinically important difference) at 12 or/and 24 weeks after therapy; and (2) mean of DLCO at 12 and 24 weeks is no less than the baseline value. MCID of DLCO improvement is 1.1 ml/min/mmHg (0.37 mmol·min -1·kPa-1) or 11% for measured value compared to baseline .

12 weeks after treatment, 24 weeks after treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change of lung diffusing capacity for carbon monoxide (DLCO) from baseline
Tidsramme: Within 52 weeks after treatment

DLCO is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.

Within 52 weeks after treatment
Change of the alveolar volume (VA) from baseline
Tidsramme: Winthin 52 weeks after treatment

Alveolar ventilation is the exchange of gas between the alveoli and the external environment. It is the process by which oxygen is brought into the lungs from the atmosphere and by which the carbon dioxide carried into the lungs in the mixed venous blood is expelled from the body.

Winthin 52 weeks after treatment
Change of images of lung by high resolution computed tomography (HR-CT) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

HR-CT images of lung will be analyzed to indicate the change of pulmonary structure.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of forced vital capacity (FVC) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

FVC is the full amount of air that can be exhaled with effort in a complete breath.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of forced expiratory volume in one second (FEV1) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

FEV1 is the volume of breath exhaled with effort in one second.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The FEV1/FVC is a ratio that reflects the amount of air you can forcefully exhale from your lungs. It's measured by spirometry, a test used to evaluate lung function.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of the diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.Since DLCO is affected by the amount of inhaled gas and lung volume, the subject's alveolar ventilation (VA) is also considered when evaluating diffusion function to exclude the effect of lung volume on diffusion volume.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of 6-minute-walk test (6MWT) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of modified medical research council (mMRC) dyspnea scale from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

It is a questionnaire to evaluate how breathlessness impacts daily activities. According to the degree of activity impacted by shortness of breath, mMRC results are divided into 0-4 grades. Grade 0 means no breathlessness except on strenuous exercise; grade 1 means shortness of breath when hurrying on the level or walking up a slight hill; grade 2 means walking slower than people of same age on the level because of breathlessness or having to stop to catch breath when walking at their own pace on the level; grade 3 means stoping for breath after walking ∼100 m or after few minutes on the level ground; and grade 4 means too breathless to leave the house, or breathless when dressing or undressing.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Change of chronic obstructive pulmonary disease Assessment Test (CAT) from baseline
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

The CAT is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT scale includes a total of 8 items, 0~5 points for each item. The total score ranges 0~40 points. Score of 0-10 points indicates slight impact; Score of 11-20 points indicates medium impact: Score of 21-30 points indicates serious impact; Score of 31-40 points indicates very serious impact.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Annual frequency of exacerbations
Tidsramme: 1 year after treatment

Frequency of exacerbations all through the year. A lower frequency means improvement of disease.

1 year after treatment
Symptoms, physical examination
Tidsramme: Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal physical examination findings.

Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
12-lead ECG
Tidsramme: 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal 12-lead Electrocardiogram (ECG).

4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Blood routine
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal laboratory test results.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Urine routine
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal laboratory test results.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Blood biochemistry
Tidsramme: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal laboratory test results.

Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Function of blood clotting
Tidsramme: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Number of cases with abnormal function of blood clotting.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Carcinoembryonic antigen (CEA)
Tidsramme: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

CEA is a tumor marker used for early diagnosis of lung cancer.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Neuron-specific enolase (NSE)
Tidsramme: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

NSE is a tumor marker significantly elevated in small cell lung cancer.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Cytokeratin-19-fragment (CYFRA21-1)
Tidsramme: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
Squamous cell carcinoma antigen (SCC)
Tidsramme: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

SCC is a specific marker for lung squamous cell carcinoma.Tumor markers are monitored to assess the safety.

Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. desember 2022

Primær fullføring (Faktiske)

9. juli 2025

Studiet fullført (Faktiske)

9. juli 2025

Datoer for studieregistrering

Først innsendt

2. november 2022

Først innsendt som oppfylte QC-kriteriene

25. november 2022

Først lagt ut (Faktiske)

6. desember 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. juli 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere